{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.06","value":"-6.1"},{"groupId":"OG001","spread":"51.28","value":"17.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"If motor dysfunction or weakness is evident, range of motion of the affected areas and/or joints will be measured by a goniometer.","dispersionType":"Standard Deviation","groups":[{"description":"Patients aged 2 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901)"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set patients who are eligible for this instrument at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months","title":"Change From Baseline in Range of Motion of PN-Associated Functional Impairment at Cycle 13.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"degrees"}